Quantum Biopharma Return on Equity (ROE) Growth & History (QNTM)
Quantum Biopharma's return on equity was −284.44% for fiscal 2025.
View full Quantum Biopharma company overviewQuantum Biopharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −284.44% | −169.52 pp |
| 2024 | 2024-12-31 | −114.92% | −33.14 pp |
| 2023 | 2023-12-31 | −81.78% | −26.02 pp |
| 2022 | 2022-12-31 | −55.76% | +22.27 pp |
| 2021 | 2021-12-31 | −78.03% | +9.59 pp |
| 2020 | 2020-12-31 | −87.62% | — |
Quantum Biopharma quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −76.14% | +129.54 pp |
| Q1 2026 | 2026-03-31 | −360.66% | −259.11 pp |
| Q4 2025 | 2025-12-31 | −38.86% | — |
| Q3 2025 | 2025-09-30 | −76.48% | −47.00 pp |
| Q2 2025 | 2025-06-30 | −205.69% | −177.97 pp |
| Q1 2025 | 2025-03-31 | −101.55% | — |
| Q3 2024 | 2024-09-30 | −29.47% | — |
| Q2 2024 | 2024-06-30 | −27.71% | — |
Quantum Biopharma return on equity trends
Over the last five fiscal years, Quantum Biopharma's return on equity decreased from −87.62% to −284.44%, a change of −196.82 percentage points. The latest reported quarter, Q2 2026, shows −76.14%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Quantum Biopharma source filings ↗